Cambridge Epigenetix (UK) wants to unlock the power of the Epigenome and become what Illumina is for NGS. And now, it has gotten the €18.9M and a new CEO needed to achieve this.
Cambrige Epigenetix is a Biotech developing epigenetic tools, and was initially founded by Cambridge Enterprise (an incubator of the University of Cambridge) and Syncona Partners – one of the top 15 VCs in Europe.
Now, Epigenetix has raised around €18.9M ($21M) in a series B round, and from very interesting investors. These are GV (formerly Google Ventures) and Sequoia Capital – one of the most prominent VCs in Silicon Valley.
This is another case of conventional Tech investors going for Biotech companies. But why did they choose this particular Biotech?
Cambridge Epigenetix was built on top on a particular piece of technology, the oxBS-Seq. This tech can sequence epigenetic modifications – which are subtle chemical differences that don’t change the genetic sequence, but change the transcription of certain genes depending on the environment.
One of the most well-studied epigenetic modifications is DNA methylation, and oxBS-Seq techniques can determine what DNA bases have this modification – and even distinguish between two of the types of methylation.
The epigenome (collection of epigenetic changes to a person’s genome over time) plays an important role in many diseases. Certain companies are even investigating it for the role it can play in Neurodegenerative disease and cancer. So, being able to sequence the epigenome could be very valuable in the future of data-driven medicine.
GV’s partner Tom Hulme (who now joins Epigenetix’s board) thinks that this concept of epigenome sequencing has as much potential as Next Generation Sequencing (NGS), and could similarly become a technological backbone in medical research. In this scenario, Epigenetix would be the next Illumina for epigenetics.
This Cambridge-based Biotech therefore seems to be aiming for this, and has even recruited a new CEO from Illumina’s ranks – Geoff Smith (former VP of Product Development).
Smith shares the same vision of epigenetic products being the next must-have for laboratories worldwide. He also considers that the new investors are key to create a data-driven tool – just like in NGS, analysing sequencing results and storing data will present as significant challenges.
Cambridge Epigenetix has big dreams, a hot field, fresh money and strong investors, both from the life sciences industry and traditional Tech. Sounds like a winning combination.